Abstract
Neurosarcoidosis involves the central and peripheral nervous system and is estimated to present symptomatically in approximately 5–16% of sarcoidosis patients. Whole-body FDG PET/MRI imaging can be used to identify sarcoid lesions in the entire body in a single examination. It can also assess response to treatment as disease activity is reflected by the degree of hypermetabolism.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Dubey N, Miletich RS, Wasay M, Mechtler LL, Bakshi R. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci. 2002;205(1):77–81.
Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. J Neurol. 2015;262(2):258–67.
Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol. 2009;30(5):953–61.
Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182(2):289–95.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
van Staalduinen, E. (2018). Neurosarcoidosis. In: PET/MR Imaging . Springer, Cham. https://doi.org/10.1007/978-3-319-65106-4_133
Download citation
DOI: https://doi.org/10.1007/978-3-319-65106-4_133
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65105-7
Online ISBN: 978-3-319-65106-4
eBook Packages: MedicineMedicine (R0)